Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

Experts discuss how bispecifics might be incorporated earlier in the lines of treatment for certain cancers, the steps that can be taken to improve access to bispecific therapies in underserved or rural community settings, and how partnerships among academic centers, manufacturers, and community practices can help accelerate the adoption of bispecific antibodies.

EP: 1.Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

EP: 2.Revolutionizing Cancer Treatment: Key Bispecific Antibody Approvals

EP: 3.How Bispecific Antibodies Are Reshaping Cancer Care

EP: 4.Optimizing Bispecific Antibody Use: Opportunities to Broaden Patient Access

EP: 5.Integrating Bispecific Antibodies in Community Oncology: Benefits and Considerations

EP: 6.Overcoming Key Operational Challenges in Integrating Bispecific Therapies

EP: 7.Partnerships in Bispecific Therapy: A Model for Supporting Community Oncology

EP: 8.Managing Complexity: Standardizing Workflows for Multiple Bispecific Therapies

EP: 9.Standardizing CRS Management and Ensuring Smooth Transitions of Care in Bispecific Therapy

EP: 10.Optimizing Bispecific Antibody Administration With EHR and Technology Solutions

EP: 11.Addressing Resource and Bandwidth Challenges in Bispecific Antibody Administration

EP: 12.Payer and Reimbursement Considerations for Bispecific Therapies

EP: 13.Emerging Therapeutic Areas for Bispecific Antibodies

Now Viewing

EP: 14.Incorporating Bispecific Antibodies Earlier in Treatment and Improving Access in Underserved Communities

EP: 15.Future Breakthroughs: What’s Next for Bispecific Antibodies in Oncology?

Video content above is prompted by the following:

1. How might bispecifics be incorporated earlier in the lines of treatment for certain cancers?
2. What steps can be taken to improve access to bispecific therapies in underserved or rural community settings?
3. How can partnerships between academic centers, manufacturers, and community practices help accelerate the adoption of bispecific antibodies?

Related Videos

Related Content

Advertisement

June 12th 2025

Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

Maggie L. Shaw

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

June 6th 2025

Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

Maggie L. Shaw

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.

Related Content

Advertisement

June 12th 2025

Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

Maggie L. Shaw

Zilucoplan (Zilbrysq; UCB) is a once-daily subcutaneous C5 complement inhibitor that has demonstrated long-term treatment benefits in patients who have acetylcholine receptor antibody–positive generalized myasthenia gravis (gMG).

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

June 10th 2025

Fixed-Duration SC Mosunetuzumab Shows 83% PFS at 1 Year in Untreated HTB Follicular Lymphoma

Mary Caffrey

Data presented at ASCO are the latest positive results for a subcutaneous version of this bispecific T-cell engager, which faces competition in follicular lymphoma.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

June 6th 2025

Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?

Mary Caffrey

Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.

June 6th 2025

Oral Ivarmacitinib Shows Promise in Atopic Dermatitis

Maggie L. Shaw

Ivarmacitinib, also known as oral SHR0302, is not yet approved by the FDA, with trials currently exploring its utility in disease settings that include atopic dermatitis and rheumatoid arthritis.